Strategic Entry into China’s Rare Disease Market

💡 Why Enter China’s Rare Disease Market Now?
China’s rare disease market is at a turning point. With evolving regulations, rising patient awareness, and digital health innovation, there’s an unprecedented opportunity for international drug makers. This whitepaper provides insights for navigating:

⚖️ Navigating NMPA & Rare Disease List

🧬 Aligning with China’s genetic testing environment

💸 Structuring pricing & reimbursement strategies

🌐 Leveraging digital health platforms

🤝 Building stakeholder & advocacy partnerships

🧪 Real-world case study of a strategic drug launch

📥 Download the Whitepaper
“Free access to the full PDF — “Fill the form“ to access the whitepaper